


Introduction to Psychedelics for Pain

A course presented by...



**PSYCHEDELICS
TODAY**



CLUSTERBUSTERS

Your Course Guide | Court Wing

REMAP Therapeutics, Founder & CEO Psychedelics & Pain Association (PPA) Co-Founder

- Performance & Pain Professional, Z-Health Master Trainer
- 14+ years formal Ki-Aikido study; Apprentice to US Chief Instructor
- Principle Programmer of UN Close Protection Diplomatic Security Physical Assessment & Preparation Course
- Assistant Instructor, RKC Kettlebell Certification for Team Six Navy SEALs
- Co-Founder/Co-Owner of NYC's first CrossFit; 14 years
- 30+ years maximizing client athletic performance, injury recovery, & pain relief

Your Course Guide | Court Wing

Study participant in NYU/Usona clinical trial of Psilocybin for Major Depressive Disorder, March 2020

By the end of “dosing” day in the trial, I was in full remission, no longer qualifying for the diagnosis of depression.

More astounding were the lateral benefits; I was also no longer suffering from low-to-moderate chronic pain and related neurological issues from previous injuries.

**This became my inspiration for this work,
and REMAP Therapeutics was born.**



Explore, develop, and innovate the intersection between **psychedelics & chronic pain**.

Created first-in-industry online course, "**Integrating Neuromuscular Rehabilitation with Psychedelics**."

World's first annual "**Psychedelics & Pain Symposium**" beginning in 2022 with top researchers in the field.

REMAP Retreats, offering evidence-informed, neurologically based psychedelic interventions for chronic pain clients.



Expanding research, understanding and access to psychedelic medicines for the treatment of chronic pain.

Creating online, community spaces for HCPs, patients, and patient advocates with evidence-informed resources.

Founded by REMAP, Clusterbusters, & Psychedelics Today.

Seed funded by RiverStyx Foundation.

We created this course to
*address a major need at a
critical moment*
in the re-emergence of
PSYCHEDELICS as MEDICINE.

PAIN must be part of the
emergent conversations around...

- ✓ **Research**
- ✓ **Applications**
 - ✓ **Access**
 - ✓ **Policy**

1 in 5 Americans suffer from chronic pain, which makes pain more prevalent than diabetes or depression.

1 in 14 Americans have “high-impact pain,” substantially restricting their daily activities.

Opioids are crucial medicines, yet **80,000 Americans died of opioid overdose in 2021.**

\$560 billion, estimated annual cost of pain in United States.

Current treatments are lacking, we need more non-addictive, comprehensive approaches to pain.

Medical Communities & Patients Need Information, mounting evidence supporting efficacy of psychedelics in treating a variety of pain conditions & comorbidities must be shared.

THE SCIENCE SPEAKS


Psychedelics have shown *signal* in treating a wide variety of pain conditions

- ✓ **Low Back Pain**, 23% of adults in the US report LBP
- ✓ **Fibromyalgia**, estimated 10 million people in the US & 3-6% of the world population
- ✓ **Cancer Pain**, 44% of cancer patients report associated pain
- ✓ **Migraine & Cluster Headaches**, 1/6 Americans and 1/5 women over a 3-month period with severe headache
- ✓ **Phantom Limb Pain**, can affect those with limb loss, crush injury, nerve damage, cancer, TBI & more
- ✓ **Complex Regional Pain Syndromes**, affects nearly 200,000 patients annually; occurs 3-4x more in women
- ✓ **Conditions of Central Sensitization**, e.g. IBS, pelvic pain, fibromyalgia, TMJ, chronic headache
- ✓ **Inflammation**, pre-clinical models show ability of some psychedelics to lower pain associated with inflammation
- ✓ Early signal in treating some **autoimmune conditions**

The People Speak | US Public Opinion on Psychedelics

Reported Psychedelic Use - 'First-Degree Connection'

Use by respondent or someone close to them defined as a 'First-Degree connection' to psychedelic use



52%

say they or someone close to them has used a psychedelic

"Keeping in mind that this survey is confidential - to the best of your knowledge, have you or has someone close to you ever used a psychedelic?"

The People Speak | US Public Opinion on Psychedelics

61% of American voters support legalizing regulated therapeutic access to psychedelics, including 35% who report “strong” support.

56% polled voters support obtaining FDA approval for psychedelics by prescription.

78% support making it easier for researchers to study psychedelic substances.

47% of voters who support therapeutic access to psychedelics also believe psychedelics are not “good for society”

49% support removing criminal penalties for personal use and possession with support for spiritual and religious use polling at just over **44%**

By comparison, it took *decades* of campaigning to get support for cannabis and same-sex marriage legislation to reach 6/10 voters. This tells us a lot.

Current Status* on Legality, Policy, & Access to Psychedelics | A Rapidly Changing Landscape.

- **21 states** pursuing legislation to decriminalize enforcement against psychedelic medicines
- **15 localities/municipalities** with either lowered legal priority, or police enforcement defunded specifically for this issue
- **2 states (OR & CO)** have both regulation and decriminalization of psychedelics
- **14 states** where psychedelics are illegal with no exceptions, statues, or active legislation
- **4 states** where psychedelics are illegal with inactive or failed legislation
- **4 states** have working groups to study medical use
- **2 states** have limited judicial exceptions
- **2 states** have reduced penalty statutes

*As of Sept. 2023

Source | Psychedelic Alpha, see resources

Pain is complex.

We need a more comprehensive understanding of pain.

Psychedelic medicines will play a role in expanding the scope of treatment and understanding of complex pain.

- Previous pain models, e.g. **Bio-Mechanical and Cartesian models**, do not fully address the complexity of pain outcome differences in severity, duration, & scope from one individual to another, even with the same pain condition.
- Psychedelics are **powerfully effective via their neurological mechanisms** of action in treating chronic pain, both centrally & peripherally AND they can also address **other key intrinsic factors, psychological & social contributors** that strongly influence the intensity of pain perception and output as we now understand them through the ***Bio-Psycho-Social and Pain Neuromatrix model***.

What to Expect from the Course

This is an introduction to the emergent field of psychedelics for pain.

This is not a practical application course.

Data driven presentations from the leaders in this field, exploring the most relevant studies & data currently available.

Resources & references throughout the course.

Access to the PPA Community and/or Network.